1. Sevenich M, Honold D, Willuweit A, Kutzsche J, Mohrlüder J, Willbold D. Development of an α-synuclein fibril and oligomer specific tracer for diagnosis of Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. Neurochem Int. 161:105422 (2022)
2. Kass B, Schemmert S, Zafiu C, Pils M, Bannach O, Kutzsche J, Bujnicki T, Willbold D. Aβ oligomer concentration in mouse and human brain and its drug-induced reduction ex vivo. Cell Rep Med. 17;3(5):100630. (2022)
3. Elfgen A, Santiago-Schübel B, Hupert, M, Schemmert S, Schartmann E, Tusche M, Gering I, Zafiu C, Kutzsche J. Oral absorption enhancement of the amyloid-β oligomer eliminating compound RD2 by conjugation with folic acid. European journal of pharmaceutical sciences: 156, 105581 (2021)
4. Post J, Kogel V, Schaffrath A, Lohmann P, Shah N J, Langen K J, Willbold D, Willuweit A, Kutzsche J. A Novel Anti-Inflammatory d-Peptide Inhibits Disease Phenotype Progression in an ALS Mouse Model. Molecules: 26 (6) (2021)
5. Camargo LC, Schöneck M, Sangarapillai N, Honold D, Shah NJ, Langen K.J, Willbold D, Kutzsche J, Schemmert S, Willuweit A. PEAβ Triggers Cognitive Decline and Amyloid Burden in a Novel Mouse Model of Alzheimer's Disease. Int J Mol Sci,. 22(13). (2021)
6. Post J, Schaffrath A, Gering I, Hartwig S, Lehr S, Shah NJ, Langen K-J, Willbold D, Kutzsche J*, Willuweit A*. Oral Treatment with RD2RD2 Impedes Development of Motoric Phenotype and Delays Symptom Onset in SOD1(G93A) Transgenic Mice. Int J Mol Sci, 22(13). (2021) *geteilte Letztautorenschaft
7. Schemmert S, Camargo L.C, Honold D, Gering I, Kutzsche J, Willuweit A, Willbold D. In Vitro and In Vivo Efficacies of the Linear and the Cyclic Version of an All-d-Enantiomeric Peptide Developed for the Treatment of Alzheimer's Disease. Int J Mol Sci, 22(12). (2021)
8. Bocharov EV, Gremer L, Urban AS, Okhrimenko IS, Volynsky PE, Nadezhdin KD, Bocharova OV, Kornilov DA, Zagryadskaya YA, Kamynina AV, Kuzmichev PK, Kutzsche J, Bolakhrif N, Müller-Schiffmann A, Dencher NA, Arseniev AS, Efremov RG, Gordeliy VI, Willbold D. All-d-Enantiomeric Peptide D3 Designed for Alzheimer's Disease Treatment Dynamically Interacts with Membrane-Bound Amyloid-β Precursors. J Med Chem. 64(22):16464-16479 (2021)
9. Camargo LC, Honold D, Bauer R, Shah NJ, Langen KJ, Willbold D, Kutzsche J, Willuweit A, Schemmert S. Sex-Related Motor Deficits in the Tau-P301L Mouse Model. Biomedicines. Sep 4;9(9):1160 (2021)
10. Kutzsche J, Jürgens D, Willuweit A, Adermann K, Fuchs C, Simons S, Windisch M, Hümpel M, Rossberg W, Wolzt M, Willbold D. Safety and Pharmacokinetics of the Orally Available Antiprionic Compound PRI-002: A Single and Multiple Ascending Dose Phase I Study. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 20;6(1):e12001 (2020)
11. Elfgen A., Hupert M, Bochinsky K, Tusche M, Gonzalez de San Roman Martin E, Gering I, Sacchi S, Pollegioni L, Huesgen PF, Hartmann R, Santiago-Schubel B, Kutzsche J * and Willbold D *. "Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-beta oligomers." Sci Rep 9(1): 5715 DOI: 10.1038/s41598-019-41993-6. (2019) *geteilte Letztautorenschaft
12. Willbold D and Kutzsche J, Do We Need Anti-Prion Compounds to Treat Alzheimer's Disease? Molecules, 2019. 24(12). (2019)
13. Zhang, T., I. Gering, J. Kutzsche, L. Nagel-Steger and D. Willbold. "Toward the Mode of Action of the Clinical Stage All-d-Enantiomeric Peptide RD2 on Abeta42 Aggregation." ACS Chem Neurosci 10(12): 4800-4809 DOI: 10.1021/acschemneuro.9b00458. (2019)
14. Schemmert S, Schartmann E, Honold D, Zafiu C, Ziehm T, Langen KJ, Shah NJ, Kutzsche J, Willuweit A, Willbold D. Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2. Neurobiol Dis. , (2018)
15. Schemmert S, Schartmann E, Zafiu C, Kass B, Hartwig S, Lehr S, Bannach O, Langen KJ, Shah NJ, Kutzsche J, Willuweit A, Willbold D. Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer's Mice with Full-blown Pathology. Mol Neurobiol. , (2018)
16. Schartmann E, Schemmert S, Niemietz N, Honold D, Ziehm T, Tusche M, Elfgen A, Gering I, Brener O, Shah NJ, Langen KJ, Kutzsche J, Willbold D, Willuweit A. In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer's Disease. J Alzheimers Dis 64(3), 859-873 (2018)
17. Schartmann E, Schemmert S, Ziehm T, Leithold LHE, Jiang N, Tusche M, Jon Shah N, Langen KJ, Kutzsche J, Willbold D, Willuweit A. Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease. Eur. J. Pharm. Sci. 114, 93-102 (2018).
18. Hupert M, Elfgen A, Schartmann E, Schemmert S, Buscher B, Kutzsche J, Willbold D, Santiago-Schübel B. Development and validation of an UHPLC-ESI-QTOF-MS method for quantification of the highly hydrophilic amyloid-β oligomer eliminating all-D-enantiomeric peptide RD2 in mouse plasma. J. Chromatogr. B 1073, 123-129 (2018).
19. Dunkelmann T, Teichmann K, Ziehm T, Schemmert S, Frenzel D, Tusche M, Dammers C, Jürgens D, Langen K-J, Demuth H-U, Shah NJ, Kutzsche J, Willuweit A, Willbold D. Aβ oligomer eliminating compounds interfere successfully with pEAβ(3–42) induced motor neurodegenerative phenotype in transgenic mice. Neuropeptides 67, 27-35 (2018).
20. Dunkelmann T, Schemmert S, Honold D, Teichmann K, Butzküven E, Demuth HU, Shah NJ, Langen KJ, Kutzsche J, Willbold D, Willuweit A. Comprehensive characterization of the pyroglutamate amyloid-β induced motor neurodegenerative phenotype of TBA2.1 mice. J Alzheimers Dis. 63, 115-130 (2108)
21. Cavini IA, Munte CE, Erlach MB, van Groen T, Kadish I, Zhang T, Ziehm T, Nagel-Steger L, Kutzsche J, Kremer W, Willbold D, Kalbitzer HR. Inhibition of amyloid Aβ aggregation by high pressures or specific d-enantiomeric peptides. Chem. Commun. 54, 3294-3297 (2108).
22. Kutzsche J, Schemmert S, Tusche M, Neddens J, Rabl R, Jürgens D, Brener O, Willuweit A, Hutter-Paier B, Willbold D. Large-scale oral treatment study with the four most promising D3-derivatives for the treatment of Alzheimer’s disease Molecules 22 (10) (2017)
23. van Groen T, Schemmert S, Brener O, Gremer L, Ziehm T, Tusche M, Nagel-Steger L, Kadish I, Schartmann AE, Elfgen A, Jürgens D, Willuweit A, Kutzsche J, Willbold The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology Sci Rep just accepted (2017)
24. Elfgen A, Santiago-Schübel B, Gremer L, Kutzsche J, Willbold D.
Surprisingly high stability of the Aβ oligomer eliminating all-D-enantiomeric peptide D3 in media simulating the route of orally administered drugs. European Journal of Pharmaceutical Sciences 107, 203-207 (2017)
25. Klein AN, Ziehm T, van Groen T, Kadish I, Elfgen A, Tusche M, Thomaier M, Reiss K, Brener O, Gremer L, Kutzsche J, Willbold D. Optimization of D-peptides for Aβ monomer binding specificity enhances their potential to eliminate toxic Aβ oligomers ACS Chem. Neurosci., 2017, 8 (9), pp 1889–1900
26. Klein AN, Ziehm T, Tusche M, Buitenhuis J, Bartnik D, Boeddrich A, Wiglenda T, Wanker E, Funke SA, Brener O, Gremer L, Kutzsche J, Willbold D. Optimization of the All-D Peptide D3 for Aβ Oligomer Elimination. PLoS One 11(4), (2016)
27. Leithold LH, Jiang N, Post J, Niemietz N, Schartmann E, Ziehm T, Kutzsche J, Shah NJ, Breitkreutz J, Langen KJ, Willuweit A, Willbold D. Pharmacokinetic properties of tandem D-peptides designed for treatment of Alzheimer's disease Eur. J. Pharm. Sci. 89, 31-38 (2016)
28. Leithold LH, Jiang N, Post J, Ziehm T, Schartmann E, Kutzsche J, Shah NJ, Breitkreutz J, Langen KJ, Willuweit A, Willbold D. Pharmacokinetic Properties of a Novel D-Peptide Developed to be Therapeutically Active Against Toxic β-Amyloid Oligomers . Pharm Res. 33, 328-336 (2016)
29. Rudolph S, Klein AN, Tusche M, Schlosser C, Elfgen A, Brener O, Teunissen C, Gremer L, Funke SA, Kutzsche J, Willbold D. Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity. PLoS One 11(2):e0147470., (2016)
30. Ziehm T, Brener O, van Groen T, Kadish I, Frenzel D, Tusche M, Kutzsche J, Reiß K, Gremer L, Nagel-Steger L, Willbold D. Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of d-Enantiomeric Peptides Designed to Eliminate Cytotoxic Aβ Species. ACS Chem Neurosci. 7 (8),1088–1096 (2016)
31. Brener O, Dunkelmann T, Gremer L, van Groen T, Mirecka EA, Kadish I, Willuweit A, Kutzsche J, Jürgens D, Rudolph S, Tusche M, Bongen P, Pietruszka J, Oesterhelt F, Langen K-J, Demuth H-U, Janssen A, Hoyer W, Funke SA, Nagel-Steger L, Willbold D QIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomers. Sci Rep 5, 13222 (2015)
32. Jiang N, Leithold LH, Post J, Ziehm T, Mauler J, Gremer L, Cremer M, Schartmann E, Shah NJ, Kutzsche J, Langen KJ, Breitkreutz J, Willbold D, Willuweit A. Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s Disease. PLoS One 10, e0128553 (2015)
33. Pattky M, Nicolardi S, Santiago-Schübel B, Sydes D, van der Burgt YE, Klein AN, Jiang N, Mohrlüder J, Hänel K, Kutzsche J, Funke SA, Willbold D, Willbold S, Huhn C. Structure characterization of unexpected covalent O-sulfonation and ion-pairing on an extremely hydrophilic peptide with CE-MS and FT-ICR-MS. Anal. Bioanal. Chem. 407, 6637-6655 (2015)
